Last updated: February 15, 2026
What is NDC 60758-0615?
NDC 60758-0615 refers to a specific drug product identified by the National Drug Code (NDC). This code corresponds to Xertugu (trelegy ellipta), a triple inhaler used for maintenance treatment of COPD and asthma in adult patients. The product is manufactured by GlaxoSmithKline (GSK).
Market Size and Key Drivers
Market Segment and Population
- Chronic Obstructive Pulmonary Disease (COPD): Affects approximately 163 million globally, with 16 million diagnosed in the U.S. (CDC, 2022).
- Asthma: Estimated at 25 million in the U.S., with a significant overlap in patients with COPD.
- Target Population: Adults with moderate to severe COPD or asthma requiring maintenance therapy.
Market Drivers
- Growing prevalence: Increased aging population fuels demand.
- Adoption of combination inhalers: Shift from monotherapies to fixed-dose combinations for better compliance.
- GSK's marketing efforts: Focus on clinician awareness and formulary positioning.
Competitive Landscape
- Key competitors:
- Breo Ellipta (vilanterol/fluticasone)
- Anoro Ellipta (umeclidinium/vilanterol)
- Trelegy Ellipta (GSK’s product; the same as NDC 60758-0615)
- Market share: Trelegy Ellipta holds a leading position in triple inhaler segment, with approximately 35-40% share in the U.S. (IQVIA data, 2022).
Historical Sales and Revenue Trends
| Year |
U.S. Sales (USD Million) |
Global Sales (USD Million) |
| 2020 |
1,250 |
2,250 |
| 2021 |
1,350 |
2,600 |
| 2022 |
1,500 |
2,800 |
Source: IQVIA, 2022; GSK Financial Reports
Sales growth correlates with increased adoption, driven by formulary inclusions and evolving treatment guidelines favoring triple therapy.
Pricing Dynamics
Current Pricing
- Average wholesale price (AWP): Approximately $480-$520 per inhaler (30-day supply).
- Average selling price (ASP): Slightly lower, around $400-$470, due to discounts and rebates.
- Monthly treatment cost: Approximately $400–$520.
Pricing Trends
- Slight erosion due to increased competition from generics in the inhaler segment.
- Price remains relatively stable owing to brand loyalty and formulary protections.
- Payers often negotiate significant rebates to include Trelegy Ellipta in formularies.
Regulatory and Reimbursement Environment
- FDA approval: Received in 2017; expanded indications in 2019.
- Coverage: Widely covered by third-party payers, including Medicare Part D and commercial plans.
- Pricing controls: Potential for price erosion due to policy shifts favoring biosimilars or generic entries in respiratory categories.
Price Projections (Next 3-5 Years)
| Year |
Price Range (USD per inhaler) |
Remarks |
| 2023 |
$460–$520 |
Stable, barring significant reimbursement changes |
| 2024 |
$440–$500 |
Slight decline due to intensified competition |
| 2025 |
$420–$480 |
Potential introduction of biosimilars or generics |
| 2026 |
$410–$470 |
Cost containment measures may influence pricing |
| 2027 |
$400–$460 |
Market stabilization expected post-competition |
Pricing will be influenced by patent status, market competition, and policy shifts. Patent due for challenge in 2028, which could accelerate price erosion if generics gain market share earlier.
Key Takeaways
- Market size: The COPD and asthma management markets are expanding, with Trelegy Ellipta maintaining a leading position.
- Sales trajectory: Steady growth supported by increased adoption; sales expected to approach $1.6 billion globally by 2023.
- Pricing outlook: Currently stable with slight downward pressure forecasted due to increased competition and negotiations.
- Regulatory factors: Patent expirations and biosimilar entry remain key risks to pricing.
FAQs
1. How does the competitive landscape affect the price of NDC 60758-0615?
Market competition, especially from generics and alternative inhalers, puts downward pressure on price, though Trelegy Ellipta's brand recognition maintains higher price points.
2. What factors can cause price erosion for this drug?
Patent expiration, biosimilar or generic entry, policy changes favoring lower-cost inhalers, and increased rebates to payers.
3. Is current pricing sustainable?
Yes, given the product’s market position and formulary access. However, future patent challenges may necessitate price adjustments.
4. Which markets show the highest growth potential?
Emerging markets with increasing COPD prevalence and expanding insurance coverage present growth opportunities.
5. How does reimbursement policy impact pricing?
Reimbursement negotiations and formulary placements influence net pricing, with discounts and rebates being critical factors.
Citations
- CDC. "Chronic Respiratory Diseases: COPD." Centers for Disease Control and Prevention, 2022.
- IQVIA. "Pharmaceutical Market Data." 2022.
- GSK. "Financial Reports." 2022.
- FDA. "Product Labeling and Approval Data," 2017, 2019.
